Resources
BeiGene Medical Europe

Pivotal phase 3 study of Zanubrutinib vs. Bendamustine

 Back View
Pivotal phase 3 study of Zanubrutinib vs. Bendamustine
 IMAGE   06/2020
 View

Pivotal phase 3 study of Zanubrutinib + Rituximab vs. Bendamustine + Rituximab in previously untreated MCL patients ineligible for SCT

Rating

Rate this resource

Related resources

Non-inferiority study comparing Zanubrutinib vs. Bendamustine
Non-inferiority study comparing Zanubrutinib vs. Bendamustine
Trial in progress: a phase 3, randomized, open-label study comparing zanubrutinib plus rituximab versus bendamustine plus rituximab in patients with previously untreated mantle cell lymphoma (MCL)
Trial in progress: a phase 3, randomized, open-label study comparing zanubrutinib plus rituximab versus bendamustine plus rituximab in patients with previously untreated mantle cell lymphoma (MCL)
Phase 1/2 study of single‑agent Zanubrutinib in patients with relapsed / refractory marginal zone lymphoma
Phase 1/2 study of single‑agent Zanubrutinib in patients with relapsed / refractory marginal zone lymphoma
 Back

Nice to see you!

For newest details on our ESMO materials in a personal video meeting, please click here!
Service